跳至主要内容
临床试验/NCT05510713
NCT05510713尚未招募不适用

Preliminary Study on the Effect of Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous

Shanghai Zhongshan Hospital0 个研究点目标入组 50 人开始时间: 2022年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
主要终点
vasoactive drugs

研究概览

简要总结

Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.)
  • presence of superior vena cava and/or inferior vena cava reflux disorders
  • age greater than 18 years

排除标准

  • Inability to establish suitable vascular access
  • Pregnant women
  • Not agreeing to active life support treatment
  • Severe active bleeding

结局指标

主要结局

vasoactive drugs

时间窗: 144 hours after dual-cannula in jugular-femoral venous

doses of vasoactive drugs

ICU mortality

时间窗: 28-day ICU mortality

Measurement of ICU mortality

次要结局

  • Cytokine(24hous after dual-cannula in jugular-femoral venous)

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Sponsor

相似试验